European journal of gastroenterology & hepatology
-
Eur J Gastroenterol Hepatol · Feb 2016
Multicenter StudyLong-term assessment of clinical response to adalimumab therapy in refractory ulcerative colitis.
The role of antitumour necrosis factor agents, in particular infliximab in ulcerative colitis (UC) has been well established. More recently adalimumab, a fully humanized antitumour necrosis factor α monoclonal antibody, was licensed for refractory moderately active UC in 2012. Available outcome data for adalimumab from routine clinical practice is limited. ⋯ Our study shows adalimumab is an effective and safe long-term therapy for moderately active UC refractory to other treatments. While this data is encouraging, further work is required on patient selection and to determine the impact of treatment on both natural history and quality of life.
-
Eur J Gastroenterol Hepatol · Feb 2016
Observational StudyModel for end-stage liver disease score in the first 3 weeks after liver transplantation as a predictor for long-term outcome.
Early allograft dysfunction after liver transplantation (LTX) is not well defined. The aim of this study was to evaluate the value of early post-transplant model for end-stage liver disease (MELD) scores for predicting long-term outcome after transplantation. ⋯ In conclusion, early postoperative MELD scores predict outcome after LTX. The postoperative MELD score at POD14 is a good predictor for patient survival and at POD7 for the graft survival after LTX.